Recap: Baxter International Q4 Earnings

 

Shares of Baxter International BAX moved higher by 0.3% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 1700.00% over the past year to $0.80, which beat the estimate of $0.76.

Revenue of $3,181,000,000 rose by 4.67% year over year, which beat the estimate of $3,040,000,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $3.35 and $3.43.

The upcoming fiscal year's revenue expected to be between $12,490,000,000 and $12,607,000,000.

Details Of The Call

Date: Feb 04, 2021

Time: 08:30 AM

ET Webcast URL: https://www.directeventreg.com/der/validateConferenceId.action

Recent Stock Performance

52-week high: $95.19

Company's 52-week low was at $69.10

Price action over last quarter: down 0.10%

Company Description

Baxter manufactures medical products across seven major reported business segments. The renal segment (32% of 2019 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while its acute therapies segment (5%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (25% of sales) sells IV pumps, administrative sets, and solutions while its nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segment (19% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (8% of sales) provides hemostastic products and biosurgical sealants. Contract manufacturing rounds out the remaining sales.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...